Lower numbers = closer to natural. Higher numbers = more enhanced.
Why this rating?
Per the NEJM Phase 2 trial (Jastreboff et al. 2023), the 12mg dose produced 24.2% mean body-weight loss at 48 weeks vs 2.1% for placebo, through triple GLP-1/GIP/Glucagon receptor activation - the glucagon component adds energy-expenditure/fat-oxidation effects beyond dual or single GLP-1 agonists. Longer follow-up (per company-reported extension data) suggests losses can climb further with continued treatment. Still investigational: Phase 3 TRIUMPH trials reached primary completion in April 2026 with no FDA approval yet. Rated 4 (one point above semaglutide/tirzepatide's 3) to reflect the larger, more aggressive metabolic effect and still-thinner long-term safety record - not because it builds muscle, which it does not.
Overview
A "triple agonist" targeting GLP-1, GIP, and Glucagon receptors. Still investigational (Phase 3 TRIUMPH trials, primary completion reached April 2026), Phase 2 data showed ~24% mean body-weight loss at 48 weeks on the 12mg dose - beyond single or dual GLP-1/GIP agonists.
Important Warnings
- •Not yet FDA approved - still in clinical trials
- •Long-term safety data not yet available
- •Must maintain high protein intake to preserve muscle
- •Grey-market "research" sourcing means unverified dose/purity and no medical oversight
- •Glucagon component can raise heart rate and fasting glucose - monitor
Purpose & Use Cases
Extreme Weight Loss
Clinical trials show ~24% body weight loss, exceeding all other options.
Metabolic Enhancement
Triple mechanism provides comprehensive metabolic improvement.
Appetite Control
Powerful appetite suppression through GLP-1 activity.
Benefits
- Unprecedented weight loss results (~24%)
- Triple mechanism of action
- Once-weekly dosing
- Improved metabolic health
- Better body composition than single agonists
Good to Know
The most powerful weight-loss drug yet: via a third (glucagon) receptor
Retatrutide is a triple agonist: GLP-1 and GIP (appetite/insulin) plus glucagon, which raises energy expenditure and fat oxidation. Phase 2 data showed around 24% body-weight loss at 48 weeks, beyond semaglutide or tirzepatide. That extra glucagon arm is both why it works so well and why heart rate and fasting glucose need watching.
Bigger, faster loss means a bigger muscle-loss risk
The same aggressiveness that makes retatrutide effective puts more lean mass on the line if you diet carelessly. Resistance training and high protein matter even more here than with milder GLP-1s. Human lean-mass data are still maturing, so this is a "protect muscle proactively" situation, not a solved one.
Still investigational: no approval, no long-term safety, grey-market sourcing
Retatrutide is in Phase 3 with no FDA approval and no long-term safety data. In practice that means physique users obtain it from grey-market "research" suppliers of unverified dose and purity, with no medical oversight of the glucagon-driven cardiovascular/glucose effects. That sourcing reality is a real part of the risk, not a footnote.
GI side effects are dose-dependent, titrate slowly
Nausea, vomiting and diarrhea track the dose and rushed increases. The 4-week titration steps exist for a reason; going slower trades a little time for far fewer GI problems.
Dosage Guidelines
| Experience Level | Dosage Range |
|---|---|
| Beginner | 1 – 2 mg/week |
| Intermediate | 4 – 8 mg/week |
| Advanced | 8 – 12 mg/week |
Phase 2/3 trials titrate from a 1-2mg starting dose in ~4-week steps up to the target maintenance dose (Phase 2 targets: 4/8/12mg; Phase 3 TRIUMPH targets: 4/9/12mg) over roughly 16 weeks before holding a steady maintenance dose. Slower titration reduces GI side effects. Since retatrutide is not FDA-approved, real-world use is exclusively via unregulated "research chemical" sourcing with unverified purity/dosing - trial protocols are the only vetted reference point.
Side Effects
Gastrointestinal Distress
very commonNausea, vomiting, diarrhea, constipation, and abdominal discomfort - common with GLP-1 activity and dose-related.
Very slow titration; smaller meals; avoid fatty foods.
Increased Heart Rate
commonGlucagon receptor activation can increase heart rate.
Monitor heart rate; typically mild and transient.
General Mitigation Strategies
Very slow 4-week titration between doses. High protein intake essential. Monitor heart rate. GI sides typically improve with time.
Support Supplements
Ancillary supplements commonly run alongside Retatrutide to manage side effects, support the target tissue, or fill nutrient demands it creates.
High protein intake
KeyBecause retatrutide drives the largest appetite drop and fastest loss of any weight agent, protein is the first thing to fall short and the main lever protecting muscle. Non-negotiable if you care about lean mass.
- Dose
- 1.2-2.0 g/kg bodyweight per day
- Timing
- Spread across meals; shakes help when appetite is crushed
Resistance training
KeyThe faster and larger the weight loss, the more lean tissue is at risk. Progressive resistance work plus adequate protein is what converts "weight loss" into "fat loss" and preserves muscle.
- Dose
- 2-4 sessions/week
- Timing
- Throughout the loss phase
Creatine monohydrate
Supports strength and lean-mass retention in a deficit; cheap and well-evidenced.
- Dose
- 3-5g/day
- Timing
- Daily
Fiber + hydration (and electrolytes)
Slowed gastric emptying and low intake cause constipation/dehydration; fiber, fluids and electrolytes manage the common GI complaints.
- Dose
- Adequate fiber; deliberate fluid/electrolyte intake
- Timing
- Daily
Post Cycle Therapy (PCT)
Not hormonal. No PCT required.
How It Works
Retatrutide activates three hormone receptors: GLP-1 (appetite suppression, insulin secretion), GIP (enhanced insulin sensitivity, fat metabolism), and Glucagon (increased energy expenditure, fat oxidation). This triple mechanism provides more comprehensive metabolic benefits than single or dual agonists.
Fundamentals
Reference on the practices relevant to Retatrutide: how they are done and where they go wrong. Not a recommendation to use it.
Legal Status
Investigational: in Phase 3 TRIUMPH trials and not yet FDA-approved as of 2026. Real-world use is exclusively via unregulated grey-market "research chemical" sourcing.
Legal status varies by country and changes over time. This is a general summary, not legal advice.
WADA Status
GLP-1/GIP/glucagon receptor agonists (including approved drugs like semaglutide and tirzepatide) are not currently listed on the WADA Prohibited List. Retatrutide is additionally still investigational and not FDA-approved.
References
- Jastreboff et al., Retatrutide Phase 2 obesity trial (NEJM 2023)
- Retatrutide, Wikipedia (mechanism, TRIUMPH Phase 3 trial status)
- Katsi et al., "Retatrutide: A Game Changer in Obesity Pharmacotherapy" (Biomolecules, PMC)
- Giblin et al.: TRIUMPH registrational Phase 3 trial design (Diabetes Obes Metab, PMC)